Maryland is currently home to 2849 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Baltimore, Bethesda, Rockville and Annapolis. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Study of Dupilumab 300 mg Every Other Week After Endoscopic Sinus Surgery in Patients With Allergic Fungal Rhinosinusitis (AFRS) on a Background Therapy With Intranasal Corticosteroid Spray
Recruiting
Background: Allergic fungal rhinosinusitis (AFRS) is a severe type of sinus infection. People with AFRS develop heavy mucus and growths called polyps that apply pressure to the sinuses and block their breathing. Surgery can remove the polyps, but they often grow back. Researchers want to test an approved drug they believe may help people with AFRS. Objective: To test a drug (Dupilumab) in people with AFRS. Eligibility: People aged 18 years or older with suspected AFRS who are scheduled to u... Read More
Gender:
All
Ages:
Between 18 years and 99 years
Trial Updated:
06/20/2024
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Allergic Fungal Rhinosinusitis (AFRS), Chronic Rhinosinusitis (CRS), Asthma, Nasal Polyps
Hemophagocytic Lymphohistiocytosis (HLH) Evaluation and Research of Clinical, ImmUnoLogic and TranscriptomE Study
Recruiting
Background: Hemophagocytic lymphohistiocytosis (HLH) is a disease caused by disrupted immune function. People with HLH are prone to fevers and illnesses, which can be fatal. Some people develop a genetic form of this disease (pHLH), but researchers do not understand why some other people develop a nongenetic form (sHLH). They also do not have good ways to diagnose and treat sHLH. Objective: To learn about sHLH and why some people get it and others do not. Eligibility: Adults aged 18 years a... Read More
Gender:
All
Ages:
Between 18 years and 120 years
Trial Updated:
06/20/2024
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Lymphohistiocytosis, Hemophagocytic, Secondary Hemophagocytic Lymphohistiocytosis, Macrophage Activation Syndrome, Hyperinflammatory Syndromes
Care Choreographies and the Making of the Psychosocial in Genetic Counseling
Recruiting
Background: Genetic counselors play a new and evolving role in medical care. Recent advances in genetic testing are changing many health care treatments, and genetic counselors play a key role in teaching people how their genes may affect both health and treatments. Genetic counselors may also help guide people through complex talks about their treatment risks; their chances for recovery; and their social and emotional health and wellbeing. Researchers want to learn more about the role genetic... Read More
Gender:
All
Ages:
Between 18 years and 115 years
Trial Updated:
06/20/2024
Locations: National Human Genome Research Institute (NHGRI), Bethesda, Maryland
Conditions: Genetic Counselor
Effects of Urolithin A Supplementation on Glucose Metabolism in Healthy Adults 55 >= Years Old: A Randomized Triple-Masked Controlled Clinical Trial
Recruiting
Background: As people age, the cells in the pancreas that produce insulin begin to release less of this hormone, and levels of blood glucose (sugar) rise. This can lead to illnesses such as diabetes. Urolithin A (UA) is a natural nutritional supplement that may improve how the body controls blood glucose. Objective: To learn if UA improves levels of insulin and other hormones that help control blood glucose. Eligibility: People aged 55 years and older with a body mass index of 27 or higher.... Read More
Gender:
All
Ages:
Between 55 years and 100 years
Trial Updated:
06/20/2024
Locations: National Institute of Aging, Clinical Research Unit, Baltimore, Maryland
Conditions: Healthy Volunteer
Measuring Protein Turnover in Humans Across the Lifespan by Metabolic Labeling With Deuterium Oxide
Recruiting
Background: Proteins are essential to the health and structure of the cells that make up body tissues. Most proteins become damaged over time and are replaced with new ones. This process is called "protein turnover." Stress, disease, and aging can affect this process. Researchers want to better understand how aging affects protein turnover. Objective: To measure rates of protein turnover in healthy adults. Eligibility: Healthy people aged 20 years and older with a body mass index between 20... Read More
Gender:
All
Ages:
Between 20 years and 120 years
Trial Updated:
06/20/2024
Locations: National Institute of Aging, Clinical Research Unit, Baltimore, Maryland
Conditions: Healthy Volunteers
A Study to Evaluate the Efficacy and Safety of NBI-1070770 in Adults With Major Depressive Disorder
Recruiting
To evaluate the efficacy, safety, and tolerability of NBI-1070770 compared to placebo on improving symptoms of depression in participants with major depressive disorder (MDD).
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
06/20/2024
Locations: Neurocrine Clinical Site, Gaithersburg, Maryland
Conditions: Major Depressive Disorder
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
Recruiting
This phase III trial tests how well the addition of dinutuximab to Induction chemotherapy along with standard of care surgical resection of the primary tumor, radiation, stem cell transplantation, and immunotherapy works for treating children with newly diagnosed high-risk neuroblastoma. Dinutuximab is a monoclonal antibody that binds to a molecule called GD2, which is found on the surface of neuroblastoma cells, but is not present on many healthy or normal cells in the body. When dinutuximab bi... Read More
Gender:
All
Ages:
30 years and below
Trial Updated:
06/20/2024
Locations: Sinai Hospital of Baltimore, Baltimore, Maryland
Conditions: Neuroblastoma, Ganglioneuroblastoma, Nodular
Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis
Recruiting
The purpose of each study is to independently measure the annualized relapse rate (ARR) with administration of frexalimab compared to a daily oral dose of teriflunomide in male and female participants with relapsing forms of multiple sclerosis (aged 18 to 55 years at the time of enrollment). People diagnosed with relapsing forms of multiple sclerosis are eligible for enrollment as long as they meet all the inclusion criteria and none of the exclusion criteria. Study details include: This event... Read More
Gender:
All
Ages:
Between 18 years and 55 years
Trial Updated:
06/20/2024
Locations: International Neurorehabilitation Institute Site Number : 8400089, Lutherville, Maryland
Conditions: Multiple Sclerosis
Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)
Recruiting
This phase II ComboMATCH treatment trial compares the effect of neratinib to the combination of neratinib and palbociclib in treating patients with HER2 positive solid tumors. Neratinib and palbociclib are in a class of medications called kinase inhibitors. They work by blocking the action of an abnormal protein that signals cancer cells to multiply. This helps slow or stop the spread of tumor cells. Giving neratinib and palbociclib in combination may shrink or stabilize cancers that over-expres... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/20/2024
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Malignant Female Reproductive System Neoplasm, Malignant Solid Neoplasm, Recurrent Malignant Female Reproductive System Neoplasm, Recurrent Malignant Solid Neoplasm
A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations
Recruiting
The primary objective of the study is to demonstrate the efficacy of high dose and low dose fluticasone propionate (Fp)/albuterol sulfate (ABS) integrated electronic module multidose dry powder inhaler (eMDPI) compared to ABS eMDPI in decreasing severe clinical asthma exacerbation (CAEs). Secondary Objectives: To evaluate the efficacy of Fp/ABS compared to ABS and the effect on systemic corticosteroid (SCS) exposure To evaluate the safety and tolerability of Fp/A BS The duration for each part... Read More
Gender:
All
Ages:
4 years and above
Trial Updated:
06/20/2024
Locations: Teva Investigational Site 15583, White Marsh, Maryland
Conditions: Asthma
MEHMO Natural History and Biomarkers
Recruiting
This observational natural history study will follow individuals with MEHMO (Mental disability, Epileptic seizure, Hypopituitarism/Hypogenitalism, Microcephaly, Obesity) syndrome or an eIF2-pathway related disorder, who have symptoms such as intellectual delay, seizures, abnormal hormone and blood sugar levels, and decreased motor skills. No current treatment for these conditions is available. A major impediment to the testing of potential therapeutic interventions is the lack of well-defined o... Read More
Gender:
All
Ages:
Between 1 week and 100 years
Trial Updated:
06/20/2024
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Intellectual Disability, Epilepsy, Hypogonadisms, Microcephaly, Nervous System Malformations, Obesity
Semaglutide Therapy for Alcohol Reduction (STAR)
Recruiting
Background: Alcohol use disorder (AUD) is a problematic pattern of alcohol use accompanied by clinically significant medical consequences. Medications can help most people reduce their drinking, but the number is limited, and additional treatment options are needed. Objective: To test if a medication named Semaglutide is safe and may reduce alcohol drinking in people with AUD. Who can participate? All Adults aged 18 or older with AUD might be eligible to participate in the study. What will... Read More
Gender:
All
Ages:
Between 18 years and 110 years
Trial Updated:
06/20/2024
Locations: National Institute on Drug Abuse, Baltimore, Maryland
Conditions: Addiction, Alcohol Use Disorder